Embedded Files
Page 25
that all current and future clinical practice guidelines for opioid analgesic prescribing are sufficient, and what research is needed to generate that evidence in a practical and feasible manner," said FDA Commissioner Scott Gottlieb, M.D., in prepared remarks. Dr. Gottlieb said the FDA plans to re-examine how opioids are being prescribed since "many common, acute indications" could be treated with "just a day or two of medication rather than a 30-day supply, which is typically prescribed." He also said the FDA is concerned about excess pills being "misused or abused by friends or family members" and the increased risks for misuse, abuse and addiction some patients may face. Strategies for the management of acute pain in medicine and dentistry are the same."This presents a difficult challenge both for the U.S. Food and Drug Administration and for health care providers," Dr. Gottlieb said. "We want to reduce the likelihood of misuse and abuse of these drugs and, at the same time, ensure our approaches are properly targeted, evidence-based and serving the medical needs of patients.""One of the ways we believe we can work together with medical professional societies as good stewards of public health is by developing a framework that can assist them in creating evidence-based guidelines on appropriate opioid analgesic prescribing to treat acute pain resulting from specific medical conditions and common surgical procedures for which these drugs are prescribed," Dr. Gottlieb concluded. "Ultimately, our public health goal is to support more rational prescribing practices."
Google Sites
Report abuse